Skip to content

Shattuck Labs, Inc. STTK Stock-Based Comp

Stock-Based Comp at other companies

Eli Lilly logo
Eli LillyLLY
$161M+4.5%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$300M+4.2%
Amgen logo
AmgenAMGN
$75M-11.8%
AbbVie logo
AbbVieABBV
$444M+8.3%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$3.2M-9.5%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$3.58M+10.3%

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s stock-based comp?
Shattuck Labs, Inc. (STTK) reported stock-based comp of $2.42M in Q1 2026.
How has Shattuck Labs, Inc.'s stock-based comp changed year-over-year?
Shattuck Labs, Inc.'s stock-based comp increased by 40.3% year-over-year, from $1.72M to $2.42M.
What is the long-term trend for Shattuck Labs, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Shattuck Labs, Inc.'s stock-based comp has grown at a 6.4% compound annual growth rate (CAGR), from $5.47M to $7M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.